History and future of omega-3 fatty acids in cardiovascular disease

References

• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67
   PubMed Web of Science ®Google Scholar
• Spector AA, Kim HY. Discovery of essential fatty acids. J Lipid Res 2015;56:11-21
   PubMed Web of Science ®Google Scholar
• Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929;82:345-67
   Google Scholar
• Sinclair HM. Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet 1956;270:381-3
   PubMed Web of Science ®Google Scholar
• Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1971;1:1143-5
   PubMed Web of Science ®Google Scholar
• Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980;33:2657-61
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958-66
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978;2:117-19
   PubMed Web of Science ®Google Scholar
• Fodor JG, Helis E, Yazdekhasti N, Vohnout B. ‘Fishing’ for the origins of the ‘Eskimos and heart disease’ story: facts or wishful thinking? Can J Cardiol 2014;30:864-8
   PubMed Web of Science ®Google Scholar
• Lands WE. Biochemistry and physiology of n-3 fatty acids. FASEB J 1992;6:2530-6
   PubMed Web of Science ®Google Scholar
• Harris WS, Shearer GC. Omega-6 fatty acids and cardiovascular disease: friend, not foe? Circulation 2014;130:1562-4
   PubMed Web of Science ®Google Scholar
• Hjermann I, Velve BK, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303-10
   PubMed Web of Science ®Google Scholar
• Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61
   PubMed Web of Science ®Google Scholar
• Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction. Eur Heart J 1994;15:1152-3
   PubMed Web of Science ®Google Scholar
• Marckmann P, Gronbaek M. Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. Eur J Clin Nutr 1999;53:585-90
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014;160:398-406
   PubMed Web of Science ®Google Scholar
• GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447-55
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
   PubMed Web of Science ®Google Scholar
• GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30
   PubMed Web of Science ®Google Scholar
• Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2010;17:588-92
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26
   PubMed Web of Science ®Google Scholar
• Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9
   PubMed Web of Science ®Google Scholar
• Blacher J, Czernichow S, Paillard F, et al. Cardiovascular effects of B-vitamins and/or N-3 fatty acids: The Su.Fol.Om3 trial. Int J Cardiol 2012;167:508-13
   PubMed Web of Science ®Google Scholar
• Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341:c6273
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
   PubMed Web of Science ®Google Scholar
• The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-8
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903
   PubMed Web of Science ®Google Scholar
• Masson S, Marchioli R, Mozaffarian D, et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. Am Heart J 2013;165:208-15
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009;73:1283-90
   PubMed Web of Science ®Google Scholar
• Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009;206:535-9
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yokoyama M, Saito Y, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 2010;74:1451-7
   PubMed Web of Science ®Google Scholar
• Wu JH, Mozaffarian D. Omega-3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. Heart 2014;100:530-3
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934
   PubMed Web of Science ®Google Scholar
• Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clin Lipidol 2014;9:149-61
   Web of Science ®Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011;13:474-83
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012;6:5-18
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36
   PubMed Web of Science ®Google Scholar
• TG and HDL Working Group of the Exome Sequencing Project NHLaBI. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-31
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015;116:665-73
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the Omega-3 fatty acids Randomized Double-blind (ORD) study. J Clin Lipidol 2013;7:199-207
   PubMed Web of Science ®Google Scholar
• Dawson K, Zhao L, Adkins Y, et al. Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men. J Nutr Biochem 2012;23:616-21
   PubMed Web of Science ®Google Scholar
• Ishida T, Ohta M, Nakakuki M, et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: Participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids 2013;88:281-8
   PubMed Web of Science ®Google Scholar
• Lovaza [package insert]. Research Triangle Park, NC, USA: GlaxoSmithKline, 2014
   Google Scholar
• Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91
   PubMedGoogle Scholar
• Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999;143:285-97
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67
   PubMed Web of Science ®Google Scholar
• Lovaza [package insert]. Research Triangle Park, NC, USA: GlaxoSmithKline, 2013
   Google Scholar
• Vascepa [package insert]. Bedminster, NJ, USA: Amarin Pharma Inc., 2015
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-90
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-92
   PubMed Web of Science ®Google Scholar
• Epanova [package insert]. Wilmington, DE, USA: AstraZeneca Pharmaceuticals LP, 2014
   Google Scholar
• Kastelein JJP, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 2014;8:94-108
   PubMed Web of Science ®Google Scholar
• Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther 2013;35:1400-11
   PubMed Web of Science ®Google Scholar
• Omtryg [package insert]. Arlington, VA, USA: Trygg Pharma Inc., 2014
   Google Scholar
• Omega-3 acid ethyl esters [package insert]. Spring Valley, NY, USA: Par Pharmaceuticals Companies Inc., 2014
   Google Scholar
• Omega-3 acid ethyl esters [package insert]. Sellersville, PA, USA: Teva Pharmaceuticals, 2014
   Google Scholar
• Nieman K, Dicklin M, Bell M, et al. Relationship between baseline triglyceride concentration and triglyceride reduction with 4 g/d long-chain omega-3 acid ethyl esters [abstract 1035.6]. FASEB J 2014;28:1035.6
   Google Scholar
• Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med 2014;126:7-18
   PubMed Web of Science ®Google Scholar
• Weitz D, Weintraub H, Fisher E, Schwartzbard AZ. Fish oil for the treatment of cardiovascular disease. Cardiol Rev 2010;18:258-63
   PubMed Web of Science ®Google Scholar
• Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract P72]. Circulation 2007;115:e238
   Web of Science ®Google Scholar
• Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord 2011;9:255-71
   PubMed Web of Science ®Google Scholar
• Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep 2015;5:7928
   PubMed Web of Science ®Google Scholar
• Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric 2015;95:1260-7
   PubMed Web of Science ®Google Scholar
• Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/ [Last accessed 9 November 2015]
   Google Scholar
• Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001;104:503-16
   PubMed Web of Science ®Google Scholar
• Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13
   PubMed Web of Science ®Google Scholar
• Eiselein L, Wilson DW, Lame MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol 2007;292:H2745-53
   Google Scholar
• Whitman SC, Miller DB, Wolfe BM, et al. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol 1997;17:1707-15
   PubMed Web of Science ®Google Scholar
• Whitman SC, Sawyez CG, Miller DB, et al. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res 1998;39:1008-20
   PubMed Web of Science ®Google Scholar
• Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74
   PubMedGoogle Scholar
• Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002;13:461-70
   PubMed Web of Science ®Google Scholar
• Fukushima H, Sugiyama S, Honda O, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004;43:2219-24
   PubMed Web of Science ®Google Scholar
• Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999;99:2858-60
   PubMed Web of Science ®Google Scholar
• Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science 1950;111:166-71
   PubMed Web of Science ®Google Scholar
• Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;2:62-6
   PubMed Web of Science ®Google Scholar
• Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013;128:1298-309
   PubMed Web of Science ®Google Scholar
• Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol 2013;12:100
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract]. Circulation 2014;130(Suppl 2):A16803
   Google Scholar
• Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 2009;3:332-40
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37-46
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose–response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011;93:243-52
   PubMed Web of Science ®Google Scholar
• Metkus TS, Timpone J, Leaf D, et al. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med 2013;14:530-9
   PubMed Web of Science ®Google Scholar
• Kelley DS, Siegel D, Fedor DM, et al. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 2009;139:495-501
   PubMed Web of Science ®Google Scholar
• Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-85
   PubMed Web of Science ®Google Scholar
• Rapp JH, Connor WE, Lin DS, Porter JM. Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques. Arterioscler Thromb 1991;11:903-11
   PubMedGoogle Scholar
• Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010;212:252-9
   PubMed Web of Science ®Google Scholar
• Amano T, Matsubara T, Uetani T, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis 2011;218:110-16
   PubMed Web of Science ®Google Scholar
• Nozue T, Yamamoto S, Tohyama S, et al. Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol 2013;111:6-11
   PubMed Web of Science ®Google Scholar
• Ando K, Watanabe T, Daidoji H, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract 12007]. Circulation 2015;132:A12007
   Web of Science ®Google Scholar
• Wurtz P, Raiko JR, Magnussen CG, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J 2012;33:2307-16
   PubMed Web of Science ®Google Scholar
• Sekikawa A, Kadowaki T, El-Saed A, et al. Differential association of docosahexaenoic and eicosapentaenoic acids with carotid intima-media thickness. Stroke 2011;42:2538-43
   PubMed Web of Science ®Google Scholar
• Wakita Y, Wakida Y, Itou T, Mizuno R. High purity eicosapentaenoic acid in addition to a strong statin makes regression of intima–media thickness in patients with asymptomatic cerebral infarction [abstract WP413]. Stroke 2013;44:WP413
   Google Scholar
• Yaemsiri S, Sen S, Tinker LF, et al. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013;44:2710-17
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Lemaitre RN, King IB, et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med 2013;158:515-25
   PubMed Web of Science ®Google Scholar
• Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis 2014;234:114-19
   PubMed Web of Science ®Google Scholar
• Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol 2014;176:577-82
   PubMed Web of Science ®Google Scholar
• Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima–media thickness in patients with type 2 diabetes. Atherosclerosis 2007;191:162-7
   PubMed Web of Science ®Google Scholar
• Nakajima K, Yamashita T, Kita T, et al. Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011;31:1963-72
   PubMed Web of Science ®Google Scholar
• Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J 2012;59:297-304
   PubMed Web of Science ®Google Scholar
• Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther 2014;28:53-9
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Shimabukuro M, Higa N, et al. Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol Res Pract 2012;2012:754181
   PubMedGoogle Scholar
• Kelley DS, Taylor PC, Nelson GJ, et al. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 1999;34:317-24
   PubMed Web of Science ®Google Scholar
• Kelley DS, Adkins Y. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc 2012;71:322-31
   PubMed Web of Science ®Google Scholar
• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 2015;242:357-66
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol 2014;8:473-88
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• McPherson R, Hegele RA. Ezetimibe: rescued by randomization (clinical and Mendelian). Arterioscler Thromb Vasc Biol 2015;35:e13-15
   PubMedGoogle Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract 2015;21(Suppl 1):1-87
   PubMed Web of Science ®Google Scholar